Scholar Rock’s New FORGE Study Puts Apitegromab to the Test in FSHD
Scholar Rock Holding (SRRK) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The FORGE Phase 2 study from Scholar Rock, Inc. tests apitegromab in people with facioscapulohumeral muscular dystrophy, or FSHD. The goal is to see if this drug can safely improve muscle function over 52 weeks, an area with very few treatment options and high unmet need.
The study drug is apitegromab, also called SRK-015, given by intravenous infusion every four weeks. It is designed to block a protein that limits muscle growth, with the aim of helping patients keep or build strength.
The trial is interventional and randomized, meaning participants are put into groups by chance. It uses a parallel design and is triple blinded, so patients, care teams, and outcome assessors do not know who gets apitegromab or placebo, keeping the focus on measuring treatment benefit.
The study is listed as Phase 2 with treatment as the main purpose. This stage helps decide if the drug’s effect is strong enough and safe enough to justify larger, more costly Phase 3 trials that investors watch closely.
The trial is not yet recruiting, with first submission recorded on 10 Feb 2026. The latest update on 24 Feb 2026 signals fresh planning activity, though primary and final completion dates are not yet posted, so the full readout is still some years away.
For investors in Scholar Rock (SRRK), this update underlines the push to broaden apitegromab beyond spinal muscular atrophy into FSHD. If early data look positive, it could support a larger addressable market in rare muscle disease and lift sentiment despite long timelines.
Competing work in FSHD remains limited, so any sign of progress here could differentiate Scholar Rock within neuromuscular small caps. Still, the not-yet-recruiting status means near term moves in the stock are more likely tied to financing plans and earlier programs than to this study alone.
The FORGE study is newly posted and planned as ongoing development, with further details and future updates available on the ClinicalTrials.gov portal.
To learn more about SRRK’s potential, visit the Scholar Rock Holding drug pipeline page.
